Lexeo Therapeutics reported third quarter 2026 financial results alongside positive interim data from its HEROIC-PKP2 trial for LX2020. The company has established a clear regulatory pathway with the FDA, which is open to using non-sustained ventricular tachycardia (NSVT) as a primary surrogate endpoint for accelerated approval, with a pivotal study expected to initiate in the second half of 2027.

Key Highlights

  • 80% mean reduction in NSVT burden observed in the high-dose LX2020 cohort at the latest assessment.
  • Cash, equivalents, and investments totaled $219.1 million as of September 30, 2026, providing a liquidity runway into 2028.
  • High-dose participants demonstrated a 44% mean reduction in premature ventricular contraction (PVC) burden.
  • LX2020 was generally well tolerated across all 10 participants with no clinically significant complement activation.